Literature DB >> 12003897

Breast screening guidelines should be adapted in Down's syndrome.

Daniel Satgé, Annie J Sasco.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 12003897      PMCID： PMC1123107     

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  Screening for breast cancer is necessary in patients with learning disability.

Authors:  J Piachaud; J Rohde
Journal:  BMJ       Date:  1998-06-27

2.  Cancer incidence among people with intellectual disability.

Authors:  K Patja; P Eero; M Iivanainen
Journal:  J Intellect Disabil Res       Date:  2001-08

3.  Risks of leukaemia and solid tumours in individuals with Down's syndrome.

Authors:  H Hasle; I H Clemmensen; M Mikkelsen
Journal:  Lancet       Date:  2000-01-15       Impact factor: 79.321

4.  [Breast cancer in women with trisomy 21].

Authors:  D Satgé; A J Sasco; H Pujol; M O Rethoré
Journal:  Bull Acad Natl Med       Date:  2001       Impact factor: 0.144

5.  Leukemia and other cancers, anomalies and infections as causes of death in Down's syndrome in the United States during 1976.

Authors:  T Scholl; Z Stein; H Hansen
Journal:  Dev Med Child Neurol       Date:  1982-12       Impact factor: 5.449
  5 in total
  3 in total

1.  Determinants of mammography in women with intellectual disabilities.

Authors:  Joanne E Wilkinson; Emily Lauer; Karen M Freund; Amy K Rosen
Journal:  J Am Board Fam Med       Date:  2011 Nov-Dec       Impact factor: 2.657

Review 2.  Primary care for women with intellectual disabilities.

Authors:  Joanne E Wilkinson; Mary C Cerreto
Journal:  J Am Board Fam Med       Date:  2008 May-Jun       Impact factor: 2.657

3.  Benefits and Harms of Mammography Screening for Women With Down Syndrome: a Collaborative Modeling Study.

Authors:  Oguzhan Alagoz; Ali Hajjar; Sarocha Chootipongchaivat; Nicolien T van Ravesteyn; Jennifer M Yeh; Mehmet Ali Ergun; Harry J de Koning; Brian Chicoine; Barry Martin
Journal:  J Gen Intern Med       Date:  2019-08-05       Impact factor: 5.128
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.